Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
By R. Mayer, E. Van Cutsem, A. Falcone, T. Yoshino, R. García-Carbonero, N. Mizunuma, K. Yamazaki, Y. Shimada, J. Tabernero, Y. Komatsu and 14 more. New England Journal of Medicine, 2015
1,249 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
Citations in the corpus
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “81) 2 [110]”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Recently, an oral agent that combines trifluridine and tipiracil hydrochloride, has been shown to be effective in the treatment of patients with refractory mCRC, leading to a significant survival benefit that is similar to that of regorafenib, but with limited toxicity and is therefore a potential n”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, background): “⑤ The efficacy and safety of TAS-102 are evaluated on the basis of J-003 study and RECOURSE study.”